Rx-To-OTC Switch Candidate Negative Lists "Stifle Innovation" - CHPA
This article was originally published in The Tan Sheet
FDA should consider all Rx-to-OTC switch candidates on a case-by-case basis and avoid creating "presumptive negative lists" of drug classes not suited to OTC use, the Consumer Healthcare Products Association stresses in Aug. 25 comments to the agency.
You may also be interested in...
NIH's National Center for Complementary & Alternative Medicine will establish its Office of Intramural Research shortly after naming a director to head the new program, an action anticipated by January.
Switching oral contraceptives for women from Rx-to-OTC status was viewed as a "good idea" by a majority of respondents to a recent survey conducted by the Guideline Research Group (New York).
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.